0000000000125697

AUTHOR

Gianluca Tornese

showing 4 related works from this author

Factors Associated With Severe Gastrointestinal Diagnoses in Children With SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome

2021

Key Points Question Is COVID-19 associated with severe gastrointestinal manifestations in children? Findings In this multicenter cohort study of 685 Italian children with COVID-19, 10% showed severe gastrointestinal involvement characterized by diffuse adeno-mesenteritis, appendicitis, abdominal fluid collection, ileal intussusception, or pancreatitis. Children older than 5 years and those presenting with abdominal pain, leukopenia, or receiving a diagnosis of multisystem inflammatory syndrome were more likely to have severe gastrointestinal manifestations. Meaning Severe gastrointestinal involvement is not uncommon in children with COVID-19, and awareness about its frequency and presentati…

MaleGastrointestinalPrognosiGastrointestinal DiseasesGastrointestinal DiseaseMultisystem Inflammatory SyndromeCOVID-19; Child; Child Preschool; Female; Gastrointestinal Diseases; Humans; Male; Prognosis; Radiography; Retrospective Studies; SARS-CoV-2; Systemic Inflammatory Response Syndromemacromolecular substancesSarsCoV2PediatricsRetrospective StudieHumansChildPreschoolChildrenOriginal InvestigationRetrospective StudiesSARS-CoV-2ResearchGastrointestinal Children SARS-CoV-2 Multisystem Inflammatory SyndromeCOVID-19General MedicinePrognosisSettore MED/38gastrointestinalSystemic Inflammatory Response SyndromeRadiographyOnline OnlyChild PreschoolFemaleSarsCoV2; COVID-19; gastrointestinalHuman
researchProduct

Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study

2021

Background: Many aspects of SARS-CoV-2 infection in children and adolescents remain unclear and optimal treatment is debated. The objective of our study was to investigate epidemiological, clinical and therapeutic characteristics of pediatric SARS-CoV-2 infection, focusing on risk factors for complicated and critical disease.Methods: The present multicenter Italian study was promoted by the Italian Society of Pediatric Infectious Diseases, involving both pediatric hospitals and general pediatricians/family doctors. All subjects under 18 years of age with documented SARS-CoV-2 infection and referred to the coordinating center were enrolled from March 2020.Results: As of 15 September 2020, 75…

Pediatricsmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MIS-CDisease030204 cardiovascular system & hematologyPediatrics03 medical and health sciences0302 clinical medicinechildren030225 pediatricsEpidemiologymedicinebookOriginal Researchmultisystem inflammatory syndromeMIS-C COVID-19business.industrySARS-CoV-2 infectionDisease progressionlcsh:RJ1-570COVID-19lcsh:PediatricsSettore MED/38Icu admissionCOVID-19; MIS-C; SARS-CoV-2 infection; children; multisystem inflammatory syndromeMulticenter studyPediatrics Perinatology and Child HealthPediatric Infectious Diseasebook.journalbusiness
researchProduct

MODELLO DI PREVISIONE DELLA STATURA FINALE IN PAZIENTI PEDIATRICI ITALIANI AFFETTI DA DEFICIT DI GH TRATTATI CON SOMATROPINA

2021

Obiettivi: elaborare un modello di previsione della statura finale in pazienti pediatrici con deficit di GH trattati con somatropina ricombinante, valutando quali siano le variabili più importanti nel determinismo della statura finale. Metodi: 1043 pazienti trattati per deficit di GH (picco di GH <10 ng/dl a 2 test di stimolo) giunti ad altezza finale. Mediana età a inizio trattamento 11 (IQR 8.7/12.8) anni; mediana altezza a inizio trattamento -2.43 (IQR -2.80/-2.01) SDS; mediana altezza bersaglio -1.09 (IQR -1.63/-0.48) SDS; dose iniziale di somatropina mediana altezza finale -1.08 SDS (IQR -1.64/-0.50 SDS, vs altezza a inizio trattamento p <0.001, vs altezza bersaglio p=ns). Analis…

Settore MED/38 - Pediatria Generale E SpecialisticaMODELLO DI PREVISIONE STATURA FINALE DEFICIT DI GHSOMATROPINA
researchProduct

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

2022

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. Results We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the pat…

Insulin-like growth factor 1Human Growth HormoneEndocrinology Diabetes and MetabolismPubertyFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; PredictionDwarfismGrowthBody HeightCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaGrowth hormone retestingPituitaryFinal heightGrowth HormoneFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; Prediction; Body Height; Child; Cohort Studies; Growth Hormone; Humans; Puberty; Dwarfism Pituitary; Human Growth HormoneHumansGrowth hormone deficiencyLMG methodDwarfism PituitaryPredictionChildFinal height Growth Growth hormone deficiency Growth hormone retesting Insulin-like growth factor 1 LMG method Prediction
researchProduct